Futami Junichiro, Nonomura Hidenori, Kido Momoko, Niidoi Naomi, Fujieda Nao, Hosoi Akihiro, Fujita Kana, Mandai Komako, Atago Yuki, Kinoshita Rie, Honjo Tomoko, Matsushita Hirokazu, Uenaka Akiko, Nakayama Eiichi, Kakimi Kazuhiro
Department of Medical Bioengineering, Graduate School of Natural Science and Technology, Okayama University , Okayama 700-8530, Japan.
Medinet Co. Ltd. , Yokohama, Kanagawa 222-0033, Japan.
Bioconjug Chem. 2015 Oct 21;26(10):2076-84. doi: 10.1021/acs.bioconjchem.5b00328. Epub 2015 Sep 22.
Humoral immune responses against tumor-associated antigens (TAAs) or cancer/testis antigens (CTAs) aberrantly expressed in tumor cells are frequently observed in cancer patients. Recent clinical studies have elucidated that anticancer immune responses with increased levels of anti-TAA/CTA antibodies improve cancer survival rates. Thus, these antibody levels are promising biomarkers for diagnosing the efficiency of cancer immunotherapy. Full-length antigens are favored for detecting anti-TAA/CTA antibodies because candidate antigen proteins contain multiple epitopes throughout their structures. In this study, we developed a methodology to prepare purified water-soluble and full-length antigens by using cysteine sulfhydryl group cationization (S-cationization) chemistry. S-Cationized antigens can be prepared from bacterial inclusion bodies, and they exhibit improved protein solubility but preserved antigenicity. Anti-TAA/CTA antibodies detected in cancer patients appeared to recognize linear epitopes, as well as conformational epitopes, and because the frequency of cysteine side-residues on the epitope-paratope interface was low, any adverse effects of S-cationization were virtually negligible for antibody binding. Furthermore, S-cationized antigen-immobilized Luminex beads could be successfully used in highly sensitive quantitative-multiplexed assays. Indeed, patients with a more broadly induced serum anti-TAA/CTA antibody level showed improved progression-free survival after immunotherapy. The comprehensive anti-TAA/CTA assay system, which uses S-cationized full-length and water-soluble recombinant antigens, may be a useful diagnostic tool for assessing the efficiency of cancer immunotherapy.
癌症患者中经常观察到针对肿瘤细胞中异常表达的肿瘤相关抗原(TAA)或癌胚抗原(CTA)的体液免疫反应。最近的临床研究表明,抗TAA/CTA抗体水平升高的抗癌免疫反应可提高癌症生存率。因此,这些抗体水平有望成为诊断癌症免疫治疗效果的生物标志物。全长抗原更有利于检测抗TAA/CTA抗体,因为候选抗原蛋白在其整个结构中包含多个表位。在本研究中,我们开发了一种利用半胱氨酸巯基阳离子化(S-阳离子化)化学方法制备纯化的水溶性全长抗原的方法。S-阳离子化抗原可从细菌包涵体制备,它们表现出改善的蛋白质溶解性但保留了抗原性。在癌症患者中检测到的抗TAA/CTA抗体似乎既能识别线性表位,也能识别构象表位,并且由于表位-抗原结合部位界面上半胱氨酸侧链残基的频率较低,S-阳离子化对抗体结合的任何不利影响实际上都可以忽略不计。此外,S-阳离子化抗原固定的Luminex微球可成功用于高灵敏度定量多重检测。事实上,血清抗TAA/CTA抗体水平诱导范围更广的患者在免疫治疗后无进展生存期得到改善。使用S-阳离子化全长和水溶性重组抗原的综合抗TAA/CTA检测系统可能是评估癌症免疫治疗效果的有用诊断工具。